Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Frontline Nivolumab Leads to Early, Durable Responses in NSCLC

July 25th 2014

One-third (30%) of chemotherapy-naïve non–small cell lung cancer (NSCLC) patients treated with nivolumab, an anti-PD-1 immune checkpoint antibody, responded to treatment in a phase I study.

MSK Continues on Groundbreaking Path in Treatment of Mesothelioma

July 23rd 2014

Although malignant pleural mesothelioma (MPM) remains a rare disease, Memorial Sloan Kettering Cancer Center has considerable experience with this malignancy, and our specialists are at the forefront of translating new approaches for the treatment of patients with mesothelioma into the clinic.

Cabozantinib Reduces Tumor Growth After Erlotinib Failure in NSCLC

July 22nd 2014

Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Giants of Cancer Care Heralded: Ceremony Honors 2nd Annual Giants Class

July 16th 2014

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

Conclusion: Addressing Unmet Needs in Lung Cancer

July 16th 2014

Potential New Biomarkers in Lung Cancer

July 16th 2014

Novel Angiogenesis Inhibitors in NSCLC

July 16th 2014

Emerging Therapies in Non-Small Cell Lung Cancer

July 16th 2014

PointBreak and AVAPERL Studies in NSCLC

July 16th 2014

Maintenance Therapy Clinical Trials for NSCLC

July 16th 2014

Role of Maintenance Therapy in NSCLC

July 16th 2014

PD-1/PD-L1 Inhibitors Across NSCLC Treatment Settings

July 16th 2014

Multiple PD-1/PD-L1 Agents in Lung Cancer

July 16th 2014

Nivolumab in Non-Small Cell Lung Cancer

July 16th 2014

PD-1 Inhibition in Lung Cancer

July 16th 2014

Efficacy of Next-Generation ALK Inhibitors

July 16th 2014

Utilizing Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

Next-Generation ALK Inhibitors in NSCLC

July 16th 2014

Frontline ALK, EGFR Inhibition in NSCLC

July 16th 2014

NEXT PAGE
PREVIOUS PAGE